Elanco

Elanco, a US-headquartered Pharmaceutical Preparation Manufacturing company, reported its 2025 emissions data as: Scope 1 at 181,624,000 kg CO2e, Scope 2 (market-based) at 303,364,000 kg CO2e, and Scope 3 at 513,589,000 kg CO2e. In 2024, Scope 1 emissions were 175,807,000 kg CO2e, market-based Scope 2 emissions were 302,607,000 kg CO2e, and Scope 3 emissions were 496,505,000 kg CO2e. For 2023, the company disclosed Scope 1 emissions of 145,021,000 kg CO2e, market-based Scope 2 emissions of 285,188,000 kg CO2e, and Scope 3 emissions of 655,353,000 kg CO2e.

Elanco is committed to several climate initiatives. The company aims to achieve net-zero Scope 1 and Scope 2 GHG emissions for its Hook office by 2030. Additionally, Elanco plans to help its customers avoid 21 million metric tons of GHG emissions by 2030, using a 2020 base year, through its products, innovation, services, and tools. The company's U.K. and Ireland affiliate has set a goal to remove internal combustion engine vehicles from the region’s fleet by 2030. Elanco is also committed to reducing Scope 1 and Scope 2 emissions across its business by working towards a 2030 goal of purchasing renewable electricity equivalent to 100% of its electricity consumption. The company is committed to long-term net-zero targets across all scopes by 2050 as per the Science Based Targets initiative (SBTi).